IL6 and COVID-19: In addition, with the emergence of SARS-CoV-2 variants, COVID-19 will not be eradicated and endemic phase is predicted if not already established [5–7] Broad spectrum anti-inflammatory agents, notably dexamethasone, Janus kinase inhibitors and interleukin-6 (IL-6) inhibitors (eg, tocilizumab) reduce mortality in hospitalized patients with severe COVID-19 disease and are commonly used in clinical practice [1].